Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Switzerland
Thailand
UK
Ukraine
Orion as an investment
Our strategy is focused on building well-being and growth driven by Innovative Medicines, while our diversified and profitable business portfolio provides stable cash flow.
Latest financial release
Stock exchange releases
- 5/15/2026 105,950 Orion Corporation A shares converted into B shares
- 4/27/2026 Composition of the Nomination Committee of Orion Corporation
- 4/23/2026 Orion Group Interim report January–March 2026
- 4/1/2026 Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
Press releases
- 5/21/2026 Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
- 5/12/2026 Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
- 4/23/2026 Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
- 4/20/2026 Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
Why Orion:
